CN112313223A - 嘧啶衍生物的药用盐及治疗病症的方法 - Google Patents

嘧啶衍生物的药用盐及治疗病症的方法 Download PDF

Info

Publication number
CN112313223A
CN112313223A CN201980042034.8A CN201980042034A CN112313223A CN 112313223 A CN112313223 A CN 112313223A CN 201980042034 A CN201980042034 A CN 201980042034A CN 112313223 A CN112313223 A CN 112313223A
Authority
CN
China
Prior art keywords
compound
methyl
pharmaceutically acceptable
cancer
salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980042034.8A
Other languages
English (en)
Chinese (zh)
Inventor
L·J·杜兰克
M·兰格斯顿
P·K·沙尔玛
T·H·阮
李双莲
X·张
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Ariad Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ariad Pharmaceuticals Inc filed Critical Ariad Pharmaceuticals Inc
Publication of CN112313223A publication Critical patent/CN112313223A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02—Dicarboxylic acids
    • C07C55/10—Succinic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
CN201980042034.8A 2018-05-14 2019-05-13 嘧啶衍生物的药用盐及治疗病症的方法 Pending CN112313223A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862671166P 2018-05-14 2018-05-14
US201862671182P 2018-05-14 2018-05-14
US62/671,166 2018-05-14
US62/671,182 2018-05-14
PCT/US2019/032002 WO2019222093A1 (en) 2018-05-14 2019-05-13 Pharmaceutical salts of pyrimidine derivatives and method of treating disorders

Publications (1)

Publication Number Publication Date
CN112313223A true CN112313223A (zh) 2021-02-02

Family

ID=68540756

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980042034.8A Pending CN112313223A (zh) 2018-05-14 2019-05-13 嘧啶衍生物的药用盐及治疗病症的方法

Country Status (11)

Country Link
US (1) US12084431B2 (https=)
EP (2) EP3793993A4 (https=)
JP (2) JP2021523208A (https=)
KR (1) KR20200144579A (https=)
CN (1) CN112313223A (https=)
AU (1) AU2019269372A1 (https=)
BR (1) BR112020023107A2 (https=)
CA (1) CA3099737A1 (https=)
MX (1) MX2020012063A (https=)
TW (1) TWI831780B (https=)
WO (1) WO2019222093A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112292378A (zh) * 2019-05-22 2021-01-29 上海翰森生物医药科技有限公司 含吲哚类衍生物抑制剂、其制备方法和应用

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3943491T (pt) 2019-03-19 2025-07-28 Voronoi Inc Derivado de heteroarilo, método para a produção do mesmo e composição farmacêutica que compreende o mesmo como componente eficaz
US12157730B2 (en) 2019-03-19 2024-12-03 Voronoi Inc. Heteroaryl derivative, method for producing same, and pharmaceutical composition comprising same as effective component
CN111303125A (zh) * 2020-04-10 2020-06-19 天津法莫西医药科技有限公司 一种甲氧基取代吲哚-嘧啶类化合物及其制备方法
TW202309022A (zh) 2021-04-13 2023-03-01 美商努法倫特公司 用於治療具egfr突變之癌症之胺基取代雜環
WO2023277172A1 (en) 2021-06-30 2023-01-05 Takeda Pharmaceutical Company Limited Process for preparing pharmaceutical salts of pyrimidine derivatives
EP4367116A4 (en) * 2021-07-07 2025-04-30 Crimson Biopharm Inc. Crystalline polymorphs of epidermal growth factor receptor inhibition, and compositions and methods therefor
JP7734995B2 (ja) * 2021-08-06 2025-09-08 上海和誉生物医薬科技有限公司 ピリミジンまたはピリジン誘導体およびその製造方法ならびに薬学上の応用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004101564A1 (en) * 2003-05-16 2004-11-25 Astrazeneca Ab Pyrimidine derivatives possessing cell-cycle inhibitory activity
CN102482277A (zh) * 2009-05-05 2012-05-30 达纳-法伯癌症研究所有限公司 表皮生长因子受体抑制剂及治疗障碍的方法
CN106559991A (zh) * 2014-06-19 2017-04-05 阿里亚德医药股份有限公司 用于激酶抑制的杂芳基化合物
CN106995437A (zh) * 2016-01-22 2017-08-01 齐鲁制药有限公司 取代吲哚或吲唑嘧啶衍生物及其制备方法和用途
WO2018049296A1 (en) * 2016-09-12 2018-03-15 Padlock Therapeutics, Inc. Heteroaryl inhibitors of pad4

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1029958C (zh) 1986-03-31 1995-10-11 联合碳化农产化学品公司 丙二酸衍生物阻滞植物生长的用途
JP2749578B2 (ja) 1986-03-31 1998-05-13 ローヌープーラン・ネーデルランド・ベー・ベー 相乗的植物成長調節剤組成物
EP0261226A1 (en) 1986-03-31 1988-03-30 Rhone Poulenc Nederland B.V. Use of malonic acid derivative compounds for increasing crop yield
EP1100788B1 (en) * 1998-07-30 2005-11-09 Wyeth Substituted quinazoline derivatives
EP1248869A2 (en) * 2000-01-07 2002-10-16 Transform Pharmaceuticals, Inc. High-throughput formation, identification, and analysis of diverse solid-forms
US7019017B2 (en) 2002-05-14 2006-03-28 Baylor College Of Medicine Small molecule inhibitors of HER2 expression
EP1778648A2 (en) 2004-08-19 2007-05-02 ICOS Corporation Compounds useful for inhibiting chk1
KR20080057296A (ko) 2005-10-21 2008-06-24 머크 앤드 캄파니 인코포레이티드 칼륨 채널 억제제
PT1948180E (pt) 2005-11-11 2013-05-10 Boehringer Ingelheim Int Tratamento de combinação de cancro compreendendo inibidores de egfr/her2
TW200826843A (en) 2006-09-13 2008-07-01 Sumitomo Chemical Co Thiadiazole compound and use thereof
FR2911138B1 (fr) 2007-01-05 2009-02-20 Sanofi Aventis Sa Nouveaux derives de n, n'-2,4-dianilinopyrimidines, leur preparation a titre de medicaments, compositions pharmaceutiques et notamment comme inhibiteurs de ikk
FR2911139A1 (fr) 2007-01-05 2008-07-11 Sanofi Aventis Sa Nouveaux derives de phenyl-(4-phenyl-pyrimidin-2-yl)amines, leur preparation a titre de medicaments, compositions pharmaceutiques et notamment comme inhibiteurs de ikk
FR2911140B1 (fr) 2007-01-05 2009-02-20 Sanofi Aventis Sa Nouveaux derives de 2-anilino 4-heteroaryle pyrimides, leur preparation a titre de medicaments, compositions pharmaceutiques et notamment comme inhibiteurs de ikk
PL2171090T3 (pl) 2007-06-08 2013-09-30 Genentech Inc Markery ekspresji genów odporności guza na leczenie hamujące HER2
CA2692379A1 (en) 2007-07-02 2009-01-08 Boehringer Ingelheim International Gmbh Antiproliferative compounds based on 5-membered heterocycles
FR2919869B1 (fr) 2007-08-09 2009-09-25 Sanofi Aventis Sa Nouveaux derives de n, n'-2,4-dianilinopyrimidines, leur preparation a titre de medicaments, compositions pharmaceutiques et notamment comme inhibiteurs de ikk
NZ603525A (en) 2008-06-27 2015-02-27 Celgene Avilomics Res Inc Pyrimidine based compound and uses thereof
CN101723936B (zh) 2008-10-27 2014-01-15 上海睿星基因技术有限公司 激酶抑制剂及其在药学中的用途
WO2010093808A1 (en) 2009-02-11 2010-08-19 Reaction Biology Corp. Selective kinase inhibitors
UY32582A (es) 2009-04-28 2010-11-30 Amgen Inc Inhibidores de fosfoinositida 3 cinasa y/u objetivo mamífero
EP2430013B1 (en) 2009-05-13 2014-10-15 Amgen Inc. Heteroaryl compounds as pikk inhibitors
WO2011082266A2 (en) 2009-12-30 2011-07-07 Arqule, Inc. Substituted heterocyclic compounds
WO2012020215A1 (en) 2010-08-09 2012-02-16 Centro Nacional De Investigaciones Oncológicas (Cnio) Amino- imidazolothiadiazoles for use as protein or lipid kinase inhibitors
US9034884B2 (en) 2010-11-19 2015-05-19 Incyte Corporation Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as JAK inhibitors
PE20140146A1 (es) 2010-11-19 2014-02-06 Incyte Corp Derivados de pirrolopiridina y pirrolopirimidina sustituidos con ciclobutilo como inhibidores de jak
JP2014513724A (ja) 2011-05-16 2014-06-05 オーエスアイ・ファーマシューティカルズ，エルエルシー 融合二環キナーゼ阻害剤
EP4119551A1 (en) 2011-07-27 2023-01-18 Astrazeneca AB 2-(2,4,5-substituted-anilino)pyrimidine compounds
CN104684906B (zh) 2012-05-11 2017-06-09 艾伯维公司 Nampt抑制剂
AR091023A1 (es) 2012-05-11 2014-12-30 Abbvie Inc Inhibidores del nampt
EP2968285A4 (en) 2013-03-13 2016-12-21 Flatley Discovery Lab COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS
WO2015039613A1 (zh) 2013-09-18 2015-03-26 北京韩美药品有限公司 抑制btk和/或jak3激酶活性的化合物
KR101879422B1 (ko) 2013-09-18 2018-07-17 베이징 한미 파마슈티컬 컴퍼니 리미티드 Btk 및/또는 jak3 키나제의 활성을 억제하는 화합물
CN104860941B (zh) 2014-02-25 2017-03-22 上海海雁医药科技有限公司 2,4‑二取代苯‑1,5‑二胺衍生物及其应用以及由其制备的药物组合物和药用组合物
EP3119763A1 (en) 2014-03-18 2017-01-25 Iteos Therapeutics Novel 3-indol substituted derivatives, pharmaceutical compositions and methods for use
GB201416754D0 (en) 2014-09-23 2014-11-05 Mission Therapeutics Ltd Novel compounds
WO2016054987A1 (zh) 2014-10-11 2016-04-14 上海翰森生物医药科技有限公司 Egfr抑制剂及其制备和应用
TWI696617B (zh) 2015-04-28 2020-06-21 大陸商上海復尚慧創醫藥研究有限公司 特定蛋白質激酶抑制劑

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004101564A1 (en) * 2003-05-16 2004-11-25 Astrazeneca Ab Pyrimidine derivatives possessing cell-cycle inhibitory activity
CN102482277A (zh) * 2009-05-05 2012-05-30 达纳-法伯癌症研究所有限公司 表皮生长因子受体抑制剂及治疗障碍的方法
CN106559991A (zh) * 2014-06-19 2017-04-05 阿里亚德医药股份有限公司 用于激酶抑制的杂芳基化合物
CN106995437A (zh) * 2016-01-22 2017-08-01 齐鲁制药有限公司 取代吲哚或吲唑嘧啶衍生物及其制备方法和用途
WO2018049296A1 (en) * 2016-09-12 2018-03-15 Padlock Therapeutics, Inc. Heteroaryl inhibitors of pad4

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
王英基等: "A New Route to N-Aryl 2-Alkenamides, N-Allyl N-Aryl 2-Alkenamides, and N-Aryl α,β-Unsaturated γ-Lac tams from N-Aryl 3-(Phenylsulfonyl)propanamides" *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112292378A (zh) * 2019-05-22 2021-01-29 上海翰森生物医药科技有限公司 含吲哚类衍生物抑制剂、其制备方法和应用
CN112292378B (zh) * 2019-05-22 2024-02-06 上海翰森生物医药科技有限公司 含吲哚类衍生物抑制剂、其制备方法和应用

Also Published As

Publication number Publication date
CA3099737A1 (en) 2019-11-21
EP3793993A1 (en) 2021-03-24
TWI831780B (zh) 2024-02-11
JP2024051160A (ja) 2024-04-10
KR20200144579A (ko) 2020-12-29
TW202015687A (zh) 2020-05-01
WO2019222093A1 (en) 2019-11-21
AU2019269372A1 (en) 2020-11-26
US12084431B2 (en) 2024-09-10
EP3793993A4 (en) 2022-01-05
BR112020023107A2 (pt) 2021-02-02
JP2021523208A (ja) 2021-09-02
MX2020012063A (es) 2021-04-13
EP4234547A3 (en) 2023-11-01
EP4234547A2 (en) 2023-08-30
US20210309640A1 (en) 2021-10-07

Similar Documents

Publication Publication Date Title
CN112313223A (zh) 嘧啶衍生物的药用盐及治疗病症的方法
WO2023116895A1 (zh) Kras抑制剂的多晶型物及其制备方法和用途
CN119350242B (zh) 靶向krasg12d的取代喹啉酮类化合物及其应用
JP2023508482A (ja) スピロ環含有キナゾリン化合物
CN101778840A (zh) ((1s)-1-(((2s)-2-(5-(4’-(2-((2s)-1-((2s)-2-((甲氧羰基)氨基)-3-甲基丁酰基)-2-吡咯烷基)-1h-咪唑-5-基)-4-联苯基)-1h-咪唑-2-基)-1-吡咯烷基)羰基)-2-甲基丙基)氨基甲酸甲酯二盐酸盐的晶型
WO2025045106A1 (zh) 一种PI3Kα抑制剂及其用途
EP3428159B1 (en) Crystalline forms of mesylate salt of pyridinyl amino pyrimidine derivative, preparation methods therefor, and applications thereof
TWI555745B (zh) 喹唑啉－７－醚化合物及其使用方法
WO2018210296A1 (zh) 一种ezh2抑制剂与btk抑制剂联合在制备治疗肿瘤的药物中的用途
TWI782523B (zh) 用作ret激酶抑制劑的化合物及其應用
JP2025535889A (ja) ピリミジン化合物の新規結晶形態、それを含有する医薬組成物、およびその使用方法
CN103717590B (zh) 喹唑啉-7-醚化合物及使用方法
WO2016140501A1 (en) Pyridine n-oxide for enhancer of zeste homolog 2 inhibitors
WO2015113521A1 (zh) 氘代喹唑啉酮化合物以及包含该化合物的药物组合物
WO2024235289A1 (zh) 用于egfr蛋白降解的化合物及其用途
JP2022548689A (ja) タンパク質アルギニンメチルトランスフェラーゼ５（ｐｒｍｔ５）の選択的阻害剤
HK40046158A (en) Pharmaceutical salts of pyrimidine derivatives and method of treating disorders
US8722884B2 (en) Pyrimidine derivatives for the treatment of abnormal cell growth
JP6961348B2 (ja) 置換されたイミダゾピリジニル−アミノピリジン化合物の塩および多型
HK40096550A (en) Pharmaceutical salts of pyrimidine derivatives and method of treating disorders
WO2020216669A1 (de) Phenylsubstituierte imidazopyridinamide und ihre verwendung
JP2025526688A (ja) 疾患を治療するためのモノカルボン酸トランスポータ４の複素環式阻害剤の塩
WO2022171018A1 (zh) 取代苯并或吡啶并嘧啶胺类抑制剂及其制备方法和应用
CN118525015A (zh) 作为fak抑制剂的化合物及其用途
KR20210072765A (ko) N-(4-플루오로-3-(6-(3-메틸피리딘-2-일)-[1,2,4]트리아졸로[1,5-a]피리미딘-2-일)페닐)-2,4-디메틸옥사졸-5-카복사미드의 고체 형태

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20211013

Address after: Osaka, Japan

Applicant after: TAKEDA PHARMACEUTICAL Co.,Ltd.

Address before: Massachusetts USA

Applicant before: ARIAD PHARMACEUTICALS, Inc.

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40046158

Country of ref document: HK

WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20210202